POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%
Clinical safety rating: safe
No significant drug interactions Can cause hypernatremia and fluid overload.
Potassium is the major intracellular cation; essential for maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac and skeletal muscle, and maintenance of normal renal function. Sodium chloride provides sodium and chloride ions, which are essential for extracellular fluid balance and acid-base balance.
| Metabolism | Potassium is primarily excreted unchanged by the kidneys; minimal metabolism. Sodium chloride is not metabolized; excreted predominantly in urine. |
| Excretion | Primarily renal (>90% excreted by kidneys); minimal fecal (<5%) and biliary elimination. Excretion is directly dependent on glomerular filtration and tubular handling. |
| Half-life | Plasma half-life is not defined for potassium as it is tightly regulated; however, the elimination of an administered dose follows a rapid distribution phase (minutes) and slower renal clearance with an effective half-life of approximately 8–12 hours in patients with normal renal function. In oliguric states, half-life is significantly prolonged. |
| Protein binding | Potassium is not significantly bound to plasma proteins; protein binding is negligible (<5%). |
| Volume of Distribution | Approximately 0.5–0.7 L/kg, reflecting distribution primarily in extracellular fluid (total body water ~0.6 L/kg). Vd is not directly clinically used for potassium dosing, as potassium is mainly intracellular. |
| Bioavailability | Intravenous: 100%. Not administered orally as a 0.224% solution in 0.9% sodium chloride (this formulation is for IV use only). |
| Onset of Action | IV infusion: onset within minutes as potassium is rapidly distributed into extracellular fluid. Immediate effect on serum potassium levels and cardiac conduction. |
| Duration of Action | Duration of action depends on dose and renal function: after IV repletion, serum potassium elevation persists for 4–6 hours; tissue stores may require 1–2 days to replete fully. Continuous infusion maintains steady levels. |
Intravenous infusion. Typically 10-20 mEq/h, not exceeding 40 mEq/h or 200 mEq per 24 hours. Rate depends on serum potassium and clinical condition.
| Dosage form | INJECTABLE |
| Renal impairment | GFR < 30 mL/min: reduce dose by 50% and monitor serum potassium closely. GFR < 15 mL/min: avoid use or use extreme caution with continuous monitoring. |
| Liver impairment | No specific Child-Pugh based adjustments. Use with caution in severe hepatic impairment due to risk of electrolyte disturbances. |
| Pediatric use | IV: 0.5-1 mEq/kg per dose, max 40 mEq per dose, infused at a rate not exceeding 0.5-1 mEq/kg/h. Monitor serum potassium frequently. |
| Geriatric use | Initiate at lower end of dosing range. Monitor renal function and serum potassium closely due to age-related decline in renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Breastfeeding | Potassium and sodium are naturally present in breast milk. Exogenous administration does not significantly alter milk concentrations. M/P ratio: not applicable as endogenous substances. Considered compatible with breastfeeding; monitor infant for electrolyte disturbances if high doses are given. |
| Teratogenic Risk | Potassium chloride and sodium chloride are endogenous substances. No teratogenic effects are expected at physiological concentrations. However, hyperkalemia or hypernatremia from excessive administration may cause fetal arrhythmias or electrolyte disturbances. First trimester: no increased risk of malformations. Second trimester: no specific risks. Third trimester: risk of fetal electrolyte imbalance if maternal levels are abnormal. |
■ FDA Black Box Warning
No FDA boxed warning.
| Common Effects | fluid replacement |
| Serious Effects |
["Hyperkalemia","Severe renal insufficiency with oliguria, anuria, or azotemia","Untreated Addison's disease","Acute dehydration","Heat cramps due to excessive sweating","Patients receiving potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride)","Concurrent use of potassium supplements unless closely monitored","Hyperchloremia or hypernatremia"]
| Precautions | ["Use with caution in renal impairment (reduced potassium excretion may lead to hyperkalemia)","Monitor serum potassium levels closely; life-threatening hyperkalemia can occur","Use with caution in patients with cardiac disease (especially if receiving digitalis)","Avoid rapid infusion to prevent localized hyperkalemia and cardiac arrest","Use with caution in conditions associated with potassium retention (e.g., severe burns, Addison's disease)","Extravasation may cause tissue necrosis; ensure proper IV placement"] |
Loading safety data…
| Fetal Monitoring | Monitor serum potassium, sodium, chloride, and renal function. In pregnant patients, assess fluid balance, urine output, and signs of hyperkalemia (ECG changes, muscle weakness) or hypernatremia (thirst, altered mental status). Fetal monitoring: if maternal electrolytes are abnormal, consider fetal heart rate monitoring for arrhythmias. |
| Fertility Effects | No direct effects on fertility reported. Electrolyte imbalances may indirectly affect reproductive function, but at therapeutic doses, no adverse impact on fertility. |